RPGLife buys Sun Pharma's seven brands at Rs 41 crore
Some of these drugs are overlap of products from the Ranbaxy, and Sun Pharma was in search of a suitable match for these drugs for more than six months
Some of these drugs are part of the overlap of products from the Ranbaxy merger and Sun Pharma was in search of a suitable match for these drugs for more than six months and sales had been declining lately. The Rs 250-crore RPG Life Sciences has bought these products that span therapy areas like heart disease, respiratory, anti-diabetes, among others.
"We want to go for high value, low competition products in India, we are looking to increase our sales from Rs 160 crore to Rs 200 crore this year," C T Renganathan, Managing Director RPG Life Sciences, told ET.
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions